Advances in Immunotherapy of Malignant Melanoma von Krajsová, I

Volltext

Importance of the Immune System and Immunotherapeutic Options in Malignant Melanoma von Krajsová, I

Volltext

Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastat... von Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroyakovskiy, D., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsová, I., Hauschild, A., Mookerjee, B., Legos, J.J., Zhang, Y., Lane, S., Schadendorf, D.

Volltext

1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant m... von Dummer, R., Flaherty, K.T., Robert, C., Arance, A., de Groot, J.W.B., Garbe, C., Gogas, H.J., Gutzmer, R., Krajsová, I., Liszkay, G., Loquai, C., Mandala, M., Schadendorf, D., Yamazaki, N., Zohren, F., Edwards, M., Ascierto, P.A.

Volltext

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments von Kandolf Sekulovic, L, Peris, K, Hauschild, A, Stratigos, A, Grob, J.-J, Nathan, P, Dummer, R, Forsea, A.-M, Hoeller, C, Gogas, H, Demidov, L, Lebbe, C, Blank, C, Olah, J, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Hansson, J, Rutkowski, P, Krajsova, I, Bylaite-Bucinskiene, M, Zalaudek, I, Maric-Brozic, J, Babovic, N, Banjin, M, Putnik, K, Weinlich, G, Todorovic, V, Kirov, K, Ocvirk, J, Zhukavets, A, Kukushkina, M, De La Cruz Merino, L, Ymeri, A, Risteski, M, Garbe, C

Volltext

PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant... von Mandala, M., Arance, A., Dummer, R., Ascierto, P.A., Gogas, H., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., Loquai, C., Tadmouri, A., Pickard, M.D., Gollerkeri, A., Robert, C., Flaherty, K.T.

Volltext

ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression... von Butler, M.O., Robert, C., Negrier, S., In, G.K., Walker, J., Krajsova, I., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Shaw, H.M., Cheng, T., Mansard, S., Grob, J.J., Guidoboni, M., Mehta, M., Ascierto, P.A., Diab, A.

Volltext

Importance of the Immune System and Immunotherapeutic Options in Malignant Melanoma von Krajsová, I

Volltext

Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma von Arance, A., Dummer, R., Ascierto, P.A., Gogas, H., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., Loquai, C., de Parseval, L.A., Pickard, M., Sandor, V., Robert, C., Flaherty, K.T.

Volltext

Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma von Dummer, R., Ascierto, P.A., Gogas, H., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., Loquai, C., de Parseval, L.A., Pickard, M., Sandor, V., Robert, C., Flaherty, K.T.

Volltext

Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma von Gogas, H., Dummer, R., Ascierto, P.A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., Loquai, C., de Parseval, L.A., Pickard, M., Sandor, V., Robert, C., Flaherty, K.T.

Volltext

More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs von Sekulovic, L. Kandolf, Peris, K., Hauschild, A., Demidov, L.V., Nathan, P., Lebbe, C., Hoeller, C., Blank, C., Olah, J., Gogas, H., Dummer, R., Bastholt, L., Herceg, D., Stratigos, A., Neyns, B., Hansson, J., Rutkowski, P., Forsea, A.-M., Krajsová, I., Garbe, C.

Volltext

3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Ve... von Robert, C, Karaszewska, B, Schachter, J, Rutkowski, P, Mackiewicz, A, Stroyakovskiy, D, Lichinitser, M, Dummer, R, Grange, F, Mortier, L, Chiarion-Sileni, V, Drucis, K, Krajsova, I, Hauschild, A, Mookerjee, B, Legos, J, Schadendorf, D

Volltext

Isolated Perfusion of the Upper Extremity with TNF-α - Double Venous Cannulation von Špaček, M, Mitáš, P, Vočka, M, Lacina, L, Hodková, G, Špunda, R, Kodet, O, Krajsová, I, Petruželka, L, Trnka, J, Kubinyi, J, Matějovský, Z, Lambert, L, Lindner, J

Volltext

Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia von Faber, Edgar, Kuba, Adam, Zapletalová, Jana, Divoká, Martina, Rožmanová, Šárka, Rohoň, Peter, Holzerová, Milena, Jarošová, Marie, Indrák, Karel

Volltext

1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mu... von Schadendorf, D., Dummer, R., Flaherty, K.T., Robert, C., Arance Fernandez, A.M., de Groot, J.W., Garbe, C., Gogas, H., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Guenzel, C.A., Polli, A., Thakur, M., di Pietro, A., Ascierto, P.A.

Volltext

786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma von Dummer, R., Pathan, N., Deng, S., Robert, C., Arance Fernandez, A.M., de Groot, J.W.B., Garbe, C., Gogas, H.J., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandala, M., Schadendorf, D., Yamazaki, N., di Pietro, A., Xie, T., Ascierto, P.A., Flaherty, K.

Volltext

An Update on Access to Novel Treatment for Metastatic Melanoma in Europe — A 2024 Survey of the European Melanoma Registry and the European Association of Dermato-Oncology von Kandolf, L, Ascierto, P, Bastholt, L, Gavrilova, I, Haanen, J, Hauschild, A, Herceg, D, Hoeller, C, Jalovcic Suljevic, A, Kessels, JI, Krajsova, I, Kukushkina, M, Lallas, A, Lorigan, P, Mangana, J, Marquez-Rodas, I, Mazilu, L, Mohr, P, Bylaite-Bucinskiene, M, Ocvirk, J, Olah, J, Putnik, K, Rutkowski, P, Saiag, P, Samolyenko, I, Schwarze, JK, Stojkovski, I, Cicmil Sarić, N, Vieira, R, Weichenthal, M, Garbe, C

Volltext

602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mut... von Haydon, A.M., Schadendorf, D., Dummer, R., Flaherty, K.T., Robert, C., Arance Fernandez, A.M., de Groot, J.W., Garbe, C., Gogas, H., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Guenzel, C.A., Polli, A., Thakur, M., Di Pietro, A., Ascierto, P.A.

Volltext

1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS von Robert, C., Flaherty, K.T., Gogas, H.J., Fernandez, A.M. Arance, Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., de Groot, J.W.B., Dutriaux, C., Loquai, C., Harney, A., Kiprilov, E., Pickard, M.D., Cantey-Kiser, J., Dummer, R., Ascierto, P.A.

Volltext